EUVIMEDEUVIMED entdecken
Crossref

Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC

Flaminia Campo, Francesca Paolini, Federica Rossi, Eleonora Guido, Debora Cacciato, Antonello Vidiri, Fulvia Pimpinelli, Aldo Venuti, Raul Pellini

European Archives of Oto-Rhino-Laryngology · 2026

DOI: 10.1007/s00405-026-10055-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2026. Verfasst von Flaminia Campo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Ita…. Hauptthemen laut MEDLINE: Papillomavirus Infections, DNA, Viral, Neoplasm Recurrence, Local, Oropharyngeal Neoplasms. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The primary objective is to determine the positive predictive value (PPV) of ctHPVDNA for diagnosis and recurrence. Secondary objectives include measuring the lead time between ctHPVDNA positivity and pathological recurrence. METHODS: ddPCR reactions were prepared with 2× ddPCR Supermix for Probes (No dUTP) (Bio-Rad) and assay-specific primers/probes targeting the E6/E7 region of HPV16, HPV33, and HPV35. Patients were included in the diagnosis cohort if they had at least one ctHPVDNA measurement obtained prior to the initiation of primary treatment. Patients were assigned to the surveillance cohort if they had at least one ctHPVDNA test performed following completion of definitive or salvage therapy. RESULTS: At diagnosis test revealed in 167 patients a PPV of 98,5% (95% CI, 94,6%-99,8%) and NPP of 97,1% (95% CI, 85,1%-99,9%). At follow up, ctHPVDNA testing demonstrated in 165 patients PPV of 96,9% (95% CI, 84,3%-99,4% [31 of 32 tests]), and NPV of 100% (95% CI, 98,9%-100% [351 of 351 tests]). There was a median lead time of positive test to event (recurrence day) of 44 days (range, 0-343 days) and mean (SD) of 143 (167,8) days. When we consider only the 11 patients enrolled at the time of the first diagnosis and followed with serial blood sampling, the median lead time was 331 days (range, 23-393 days) and mean (SD) of 233 (156,7) days. CONCLUSION: ctHPVDNA represents a promising dynamic biomarker for diagnosis and Follow-up. Incorporation of ctHPVDNA kinetics into follow-up protocols may reduce reliance on frequent imaging, enabling a targeted follow-up strategy and allowing earlier detection of recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsDNA, ViralNeoplasm Recurrence, LocalOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckHuman Papillomavirus VirusesHumansFemaleMaleMiddle AgedPredictive Value of TestsPolymerase Chain ReactionFollow-Up StudiesAged

Stichwörter der Autor:innen

Circulating tumor DNA (ctDNA)Follow upHead and neck cancerHuman papillomavirus (HPV)Liquid biopsyOropharynx squamous cell carcinoma

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy. flaminia.campo@ifo.it.
  • HPV- Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
  • Department of Biochemical Sciences A. Rossi Fanelli, Sapienza University of Rome, Rome, Italy.
  • Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
  • Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
  • Department of Microbiology and Virology, IRCCS San Gallicano Dermatological Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.

Zitieren

APA

Campo, F., Paolini, F., Rossi, F., Guido, E., Cacciato, D., Vidiri, A., Pimpinelli, F., Venuti, A., & Pellini, R. (2026). Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10055-9

Vancouver

Campo F, Paolini F, Rossi F, Guido E, Cacciato D, Vidiri A, et al. Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10055-9

BibTeX
@article{Campo2026,
  author = {Campo, Flaminia and Paolini, Francesca and Rossi, Federica and Guido, Eleonora and Cacciato, Debora and Vidiri, Antonello and Pimpinelli, Fulvia and Venuti, Aldo and Pellini, Raul},
  title = {Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  doi = {10.1007/s00405-026-10055-9}
}
Kostenlos starten →